Abstract
Background: Lithium has been considered the "gold standard" in the management of bipolar disorder, being the agent compared with "new mood stabilizer". It has also shown effect in the reduction of suicidal thoughts. Among the known mechanisms of action of lithium it has been described the inhibition in inositol monophosphatase (IMP) as resulting in non-competitive inhibition of IMP, resulting in a decrease of inositol in the central nervous system leading to a decrease in the synthesis of inositol triphosphate, affecting the transmission and translation of signals. Added to this, lithium inhibits kinase glycogen synthase enzyme (GSK) 3-β; it’s regulated by different signaling pathways and its dysfunction has been related to the pathophysiology of mood disorders, schizophrenia, diabetes and Alzheimer's disease. The neuroprotective effects have been shown of lithium in preclinical studies. The chronic administration of lithium enhances the proliferation of progenitor cells and inhibits cell loss induced by glutamate and glucocorticoids. In addition to a neurotrophic and neuroprotective role, lithium can also exert beneficial effect through its ability to improve mitochondrial function.
Objective: Our aim was to explore the current information on the findings relating to lithium as a substance with possible neuroprotector effect in patients with diagnosis of bipolar disorder, as well as other conditions.
Method: We performed a literature review regarding the use of Lithium and its potential neuroprotective effect in patients
Conclusion: There is enough evidence that lithium may slow the progression of neurocognitive impairment in long term treatment patients, suggesting a potential use for the treatment of neurodegenerative diseases.
Keywords: Bipolar disorder, mood disorders, lithium, neuroprotection, neurodegenerative, mood stabilizer.
Graphical Abstract
Current Psychopharmacology
Title:Neuroprotective Effects of Lithium in Patients with Bipolar Disorder
Volume: 4
Author(s): Claudia Becerra-Palars, Javier Amado-Lerma, Alejandra Andrade, Rafael Campuzano and Emilio Montemayor
Affiliation:
Keywords: Bipolar disorder, mood disorders, lithium, neuroprotection, neurodegenerative, mood stabilizer.
Abstract: Background: Lithium has been considered the "gold standard" in the management of bipolar disorder, being the agent compared with "new mood stabilizer". It has also shown effect in the reduction of suicidal thoughts. Among the known mechanisms of action of lithium it has been described the inhibition in inositol monophosphatase (IMP) as resulting in non-competitive inhibition of IMP, resulting in a decrease of inositol in the central nervous system leading to a decrease in the synthesis of inositol triphosphate, affecting the transmission and translation of signals. Added to this, lithium inhibits kinase glycogen synthase enzyme (GSK) 3-β; it’s regulated by different signaling pathways and its dysfunction has been related to the pathophysiology of mood disorders, schizophrenia, diabetes and Alzheimer's disease. The neuroprotective effects have been shown of lithium in preclinical studies. The chronic administration of lithium enhances the proliferation of progenitor cells and inhibits cell loss induced by glutamate and glucocorticoids. In addition to a neurotrophic and neuroprotective role, lithium can also exert beneficial effect through its ability to improve mitochondrial function.
Objective: Our aim was to explore the current information on the findings relating to lithium as a substance with possible neuroprotector effect in patients with diagnosis of bipolar disorder, as well as other conditions.
Method: We performed a literature review regarding the use of Lithium and its potential neuroprotective effect in patients
Conclusion: There is enough evidence that lithium may slow the progression of neurocognitive impairment in long term treatment patients, suggesting a potential use for the treatment of neurodegenerative diseases.
Export Options
About this article
Cite this article as:
Becerra-Palars Claudia, Amado-Lerma Javier, Andrade Alejandra, Campuzano Rafael and Montemayor Emilio, Neuroprotective Effects of Lithium in Patients with Bipolar Disorder, Current Psychopharmacology 2015; 4 (2) . https://dx.doi.org/10.2174/2211556005666151216225423
DOI https://dx.doi.org/10.2174/2211556005666151216225423 |
Print ISSN 2211-5560 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-5579 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Aquaporin and Blood Brain Barrier
Current Neuropharmacology Blocking Receptor Protein Tyrosine Phosphatase β /ζ: A Potential Therapeutic Strategy for Parkinsons Disease
Current Medicinal Chemistry Treatment of Pancreatic Cancer with Pharmacological Ascorbate
Current Pharmaceutical Biotechnology Anesthetic Neuroprotection: Antecedents and An Appraisal of Preclinical and Clinical Data Quality
Current Pharmaceutical Design A High-Throughput Screening Assay for Determining Cellular Levels of Total Tau Protein
Current Alzheimer Research Fatty Acid Amide Hydrolase: A Potential Target for Next Generation Therapeutics
Current Pharmaceutical Design VEGF Signaling in Cancer Treatment
Current Pharmaceutical Design Gene Therapy for Ischemic Brain Diseases
Current Gene Therapy Aspartic Protease Inhibitors as Potential Anti-Candida albicans Drugs: Impacts on Fungal Biology, Virulence and Pathogenesis
Current Medicinal Chemistry Imidazoline Receptor Agonists for Managing Hypertension May Hold Promise for Treatment of Intracerebral Hemorrhage
Current Molecular Medicine Gene Patents in the Primary Prevention of Vascular Diseases
Recent Patents on DNA & Gene Sequences Emerging Advances in Nanomedicine as a Nanoscale Pharmacotherapy in Rheumatoid Arthritis: State of the Art
Current Topics in Medicinal Chemistry Therapeutic Challenges in Neuroendocrine Tumors
Anti-Cancer Agents in Medicinal Chemistry Cytokines in HIV-Infection - Inflammatory Damage or Therapeutic Potential?
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Mesenchymal Stromal Cell Therapy for Cardio Renal Disorders
Current Pharmaceutical Design Therapeutic Implications of Superoxide Dismutase And Its Importance in Kinase Drug Discovery
Current Topics in Medicinal Chemistry Genistein as a Potential Anticancer Agent Against Head and Neck Squamous Cell Carcinoma
Current Topics in Medicinal Chemistry Brain Inflammation, Cholesterol, and Glutamate as Interconnected Participants in the Pathology of Alzheimers Disease
Current Pharmaceutical Design PDGF Receptor β Signaling in Pericytes Following Ischemic Brain Injury
Current Neurovascular Research Estrogen Receptor Neurobiology and its Potential for Translation into Broad Spectrum Therapeutics for CNS Disorders
Current Molecular Pharmacology